BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

First patients receive Moderna’s coronavirus vaccine  Moderna Inc. (NASDAQ:MRNA) said NIH has begun dosing patients in a Phase I study of mRNA-1273, the company’s vaccine against SARS-CoV-2. The trial is enrolling 45 healthy adults at...
BC Extra | Oct 25, 2019
Clinical News

Galapagos optimistic on filgotinib beyond RA, despite two misses

Galapagos remained positive on filgotinib’s development in autoimmune diseases outside of rheumatoid arthritis, despite a pair of failures in cutaneous lupus and Sjögren syndrome. “I’m personally excited about these results,” Walid Abi-Saab, CMO of Galapagos...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BC Week In Review | May 4, 2017
Clinical News

FDA approves companion diagnostic for AML drug Rydapt

Invivoscribe Technologies Inc. (San Diego, Calif.) said FDA approved its Leukostrat CDx FLT3 Mutation Assay as a companion diagnostic for acute myelogenous leukemia (AML) drug Rydapt midostaurin from Novartis AG (NYSE:NVS; SIX:NOVN). The in vitro...
BC Week In Review | Feb 24, 2017
Company News

Promega, Thermo Fisher supply/service news

The U.S. Supreme Court ruled that Life Technologies Corp. is not liable for patent infringement under U.S. law for selling Promega’s kit overseas because only one of the five components were manufactured in the U.S....
BC Extra | Jan 19, 2017
Company News

Management tracks

Cancer company Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) named Richard Peters president and CEO, effective Feb. 6. He was SVP and head of global rare diseases at the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Fibrosis and inflammation...
BC Innovations | Apr 7, 2016
Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences  The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...
BC Extra | Apr 2, 2015
Company News

Management tracks

Antibody-drug conjugate company ImmunoGen Inc. (NASDAQ:IMGN) hired Anna Berkenblit as VP and CMO. Berkenblit was SVP of clinical development at H3 Biomedicine Inc. (Cambridge, Mass.). Ear disease company Otonomy Inc. (NASDAQ:OTIC) named Dean Hakanson CMO....
BC Week In Review | Mar 23, 2015
Company News

Enzo, Thermo Fisher genomics news

The U.S. Court of Appeals for the Federal Circuit (CAFC) vacated a lower court judgment that Life Technologies Corp .’s sequencing instruments infringed Enzo’s U.S. Patent No. 5,449,767, covering DNA sequencing compounds. The appeals court...
BC Week In Review | Oct 27, 2014
Clinical News

Lyra Parainfluenza Assay regulatory update

Quidel said FDA granted 510(k) clearance to the company's Lyra Parainfluenza Assay to quantitatively detect human parainfluenza virus (HPIV) infections types 1, 2 or 3 viral RNA from nasal swab and nasopharyngeal swab specimens. The...
Items per page:
1 - 10 of 970
BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

First patients receive Moderna’s coronavirus vaccine  Moderna Inc. (NASDAQ:MRNA) said NIH has begun dosing patients in a Phase I study of mRNA-1273, the company’s vaccine against SARS-CoV-2. The trial is enrolling 45 healthy adults at...
BC Extra | Oct 25, 2019
Clinical News

Galapagos optimistic on filgotinib beyond RA, despite two misses

Galapagos remained positive on filgotinib’s development in autoimmune diseases outside of rheumatoid arthritis, despite a pair of failures in cutaneous lupus and Sjögren syndrome. “I’m personally excited about these results,” Walid Abi-Saab, CMO of Galapagos...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BC Week In Review | May 4, 2017
Clinical News

FDA approves companion diagnostic for AML drug Rydapt

Invivoscribe Technologies Inc. (San Diego, Calif.) said FDA approved its Leukostrat CDx FLT3 Mutation Assay as a companion diagnostic for acute myelogenous leukemia (AML) drug Rydapt midostaurin from Novartis AG (NYSE:NVS; SIX:NOVN). The in vitro...
BC Week In Review | Feb 24, 2017
Company News

Promega, Thermo Fisher supply/service news

The U.S. Supreme Court ruled that Life Technologies Corp. is not liable for patent infringement under U.S. law for selling Promega’s kit overseas because only one of the five components were manufactured in the U.S....
BC Extra | Jan 19, 2017
Company News

Management tracks

Cancer company Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) named Richard Peters president and CEO, effective Feb. 6. He was SVP and head of global rare diseases at the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Fibrosis and inflammation...
BC Innovations | Apr 7, 2016
Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences  The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...
BC Extra | Apr 2, 2015
Company News

Management tracks

Antibody-drug conjugate company ImmunoGen Inc. (NASDAQ:IMGN) hired Anna Berkenblit as VP and CMO. Berkenblit was SVP of clinical development at H3 Biomedicine Inc. (Cambridge, Mass.). Ear disease company Otonomy Inc. (NASDAQ:OTIC) named Dean Hakanson CMO....
BC Week In Review | Mar 23, 2015
Company News

Enzo, Thermo Fisher genomics news

The U.S. Court of Appeals for the Federal Circuit (CAFC) vacated a lower court judgment that Life Technologies Corp .’s sequencing instruments infringed Enzo’s U.S. Patent No. 5,449,767, covering DNA sequencing compounds. The appeals court...
BC Week In Review | Oct 27, 2014
Clinical News

Lyra Parainfluenza Assay regulatory update

Quidel said FDA granted 510(k) clearance to the company's Lyra Parainfluenza Assay to quantitatively detect human parainfluenza virus (HPIV) infections types 1, 2 or 3 viral RNA from nasal swab and nasopharyngeal swab specimens. The...
Items per page:
1 - 10 of 970